Calidi Biotherapeutics (CLDI) Depreciation & Amortization - Total (2024 - 2026)

Calidi Biotherapeutics has reported Depreciation & Amortization - Total for 3 years, with the latest figure at $89000.0 in Q2 2026.

• On a quarterly basis, Depreciation & Amortization - Total fell 7.29% year-over-year to $89000.0 in Q2 2026; TTM through Jun 2026 was $384000.0, a 3.03% decrease from a year earlier, with the FY2025 full-year figure at $386000.0, down 3.98% from the prior year.
• Depreciation & Amortization - Total was $89000.0 for Q2 2026 at Calidi Biotherapeutics, down from $94000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization - Total was $105000.0 in Q3 2025, with the low at $89000.0 in Q2 2026.
• Average Depreciation & Amortization - Total over 3 years is $97714.3, with a median of $99000.0 recorded in 2024.
• The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization - Total advanced 6.06% in 2025, then retreated 7.29% in 2026.
• Over 3 years, Depreciation & Amortization - Total stood at $100000.0 in 2024, then dropped by 6.0% to $94000.0 in 2025, then fell by 5.32% to $89000.0 in 2026.
• The last three Depreciation & Amortization - Total figures came in at $89000.0 (Q2 2026), $94000.0 (Q4 2025), and $105000.0 (Q3 2025), per Business Quant data.